Skip to main content
Premium Trial:

Request an Annual Quote

CancerIQ Closes $14M Series B Funding Round

NEW YORK – CancerIQ said Thursday that it has completed a $14 million Series B round of venture capital.

Merck Global Health Innovation Fund and Amgen Ventures led the round, with participation from McKesson Ventures, OSF Ventures, and HealthX Ventures. OSF Ventures is the investment arm of CancerIQ customer OSF HealthCare, while HealthX Ventures led CancerIQ's $4.8 million Series A in 2020.

The Chicago-based firm will use the new funding to augment its precision health technology platform, form new partnerships, and expand its customer base, which consists of healthcare delivery systems. The company also expects to add about 50 additional employees.

"The cancer research community has made great strides in cancer prevention and treatment," CancerIQ cofounder and CSO Olufunmilayo Olopade said in a statement. "But now we must accelerate and scale the clinical pipeline, so a diverse population of patients — those receiving care at academic medical centers and community hospitals alike — can benefit from these advances."

Olopade, founder of the Center for Clinical Cancer Genetics at the University of Chicago, is the mother of CancerIQ cofounder and CEO Feyi Olopade Ayodele.

"CancerIQ's vision is to end cancer as we know it by eliminating health disparities and democratizing access to the latest advances in cancer early detection and prevention," Ayodele said. "We started by making genetic testing more accessible and connecting patients to the right preventive services at the right time. This latest round of funding will help CancerIQ reach more patients and connect to more innovations that promise to transform cancer from a deadly disease to a manageable condition."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.